Abstract: Radioimmunotherapy combines the physical killing effect of radionuclides and the targeting specificity of antibodies, which can effectively kill tumor cells and reduce damage to healthy tissues, and has become an increasingly indispensable means and tool in precision treatment of tumor. With the maturity of nuclide preparation technology and the extensive clinical application of antibody drugs, great progress of radioimmunotherapy antibody has been made in tumor diagnosis and treatment. Based on the preclinical research and clinical trials of radiolabeled antibody drugs in recent years, this article introduces in detail the research progress and application values of monoclonal antibodies, single domain antibodies and pre-targeting strategies in the field of radioimmunotherapy, aiming to provide new ideas and directions for the target-specific paired diagnosis and treatment in tumor.